Abstract
CGRP Monoclonal Antibodies for Prevention of Migraine: There are Many Adverse Effects
Highlights
Assistant Professor of Neurology, Chicago Medical School, North Chicago, Illinois, USA Director, Robbins Headache Clinic, Riverwoods, Illinois, USA
This letter is in response to the excellent July, 2020 article “Migraine and CGRP Monoclonal Antibodies: A Review of Cardiovascular Side Effects and Safety Profile” (Boldig and Butala) [1]
There are a plethora of adverse effects (AEs) from the CGRP monoclonals that were not identified in the Phase 3 trials
Summary
Assistant Professor of Neurology, Chicago Medical School, North Chicago, Illinois, USA Director, Robbins Headache Clinic, Riverwoods, Illinois, USA. There are a plethora of adverse effects (AEs) from the CGRP monoclonals (mAbs) that were not identified in the Phase 3 trials. The package insert (PI) for the CGRP mAbs, as with many of the new drugs, identifies few AEs. The reasons for this include: 1.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
